BRPI0607676A2 - anticorpos contra isoformas de cspcna e usos destes - Google Patents

anticorpos contra isoformas de cspcna e usos destes

Info

Publication number
BRPI0607676A2
BRPI0607676A2 BRPI0607676-9A BRPI0607676A BRPI0607676A2 BR PI0607676 A2 BRPI0607676 A2 BR PI0607676A2 BR PI0607676 A BRPI0607676 A BR PI0607676A BR PI0607676 A2 BRPI0607676 A2 BR PI0607676A2
Authority
BR
Brazil
Prior art keywords
cspcna
isoforms
antibodies against
isoform
cell proliferation
Prior art date
Application number
BRPI0607676-9A
Other languages
English (en)
Inventor
Robert J Hickey
Linda H Malkas
Lauren Schnaper
Original Assignee
Univ Indiana Res & Tech Corp
Cs Keys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp, Cs Keys Inc filed Critical Univ Indiana Res & Tech Corp
Publication of BRPI0607676A2 publication Critical patent/BRPI0607676A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Abstract

ANTICORPOS CONTRA ISOFORMAS DE CSPCNA E USOS DESTES. São descritos anticorpos que se ligam especificamente somente a uma isoforma de antígeno nuclear de proliferação celular específico de câncer (csPCNA) e não à isoforma de antígeno nuclear de proliferação celular não maligna (nmPCNA> Também são descritos métodos e composições para detectar a presença da isoforma de csPCNA.
BRPI0607676-9A 2005-04-27 2006-04-27 anticorpos contra isoformas de cspcna e usos destes BRPI0607676A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67527505P 2005-04-27 2005-04-27
US68961405P 2005-06-09 2005-06-09
PCT/US2006/016096 WO2006116631A2 (en) 2005-04-27 2006-04-27 Cancer specific pcna isoform binding antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0607676A2 true BRPI0607676A2 (pt) 2009-09-22

Family

ID=37215524

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607676-9A BRPI0607676A2 (pt) 2005-04-27 2006-04-27 anticorpos contra isoformas de cspcna e usos destes

Country Status (10)

Country Link
US (4) US20080206140A1 (pt)
EP (1) EP1874823B1 (pt)
JP (1) JP2008539271A (pt)
AU (1) AU2006239318A1 (pt)
BR (1) BRPI0607676A2 (pt)
CA (1) CA2605745A1 (pt)
EA (1) EA200702361A1 (pt)
HK (1) HK1110338A1 (pt)
MX (1) MX2007013584A (pt)
WO (1) WO2006116631A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294471B2 (en) * 2002-02-27 2007-11-13 Cskeys, Llc Method for purifying cancer-specific proliferating cell nuclear antigen
US8653039B2 (en) 2006-02-17 2014-02-18 Robert J. Hickey Peptide based inhibition of caPCNA interaction in cancer
CA3023068C (en) * 2008-07-24 2022-06-21 Indiana University Research And Technology Corporation Cancer peptide therapeutics
US20120195978A1 (en) * 2009-10-07 2012-08-02 Indiana University Research And Technology Corpora Capcna peptide therapeutics for cancer
US8455200B2 (en) 2009-10-15 2013-06-04 Traxxsson, Llc Measurement of PKA for cancer detection
EP2688566A4 (en) * 2011-03-23 2014-09-10 Univ Indiana Res & Tech Corp ANTICANCER THERAPEUTIC AGENTS
US10451633B2 (en) * 2014-03-24 2019-10-22 IMMCO Diagnostics, Inc. Anti-nuclear antibody detection and diagnostics for systemic and non-systemic autoimmune disorders
US10420840B2 (en) 2015-04-10 2019-09-24 Rll, Llc Anticancer therapeutic agents
IL267340B2 (en) * 2016-12-15 2023-12-01 Nat Inst Biotechnology Negev Ltd Monoclonal antibodies against PCNA and their use
CA3103629A1 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU750082B2 (en) * 1997-09-29 2002-07-11 University Of Maryland At Baltimore Altered DNA synthesome components as biomarkers for malignancy
US7294471B2 (en) * 2002-02-27 2007-11-13 Cskeys, Llc Method for purifying cancer-specific proliferating cell nuclear antigen
EP1998177A3 (en) * 2003-01-06 2009-02-18 Wyeth Compositions and methods for diagnosing and treating colon cancers
CN101632020B (zh) * 2006-09-13 2013-11-27 昂西免疫有限公司 改进的免疫测定方法

Also Published As

Publication number Publication date
EP1874823A2 (en) 2008-01-09
AU2006239318A8 (en) 2006-11-02
WO2006116631A3 (en) 2007-03-22
US20180362626A1 (en) 2018-12-20
EA200702361A1 (ru) 2008-04-28
WO2006116631A2 (en) 2006-11-02
EP1874823B1 (en) 2016-01-13
US20150259407A1 (en) 2015-09-17
HK1110338A1 (zh) 2008-07-11
US20120244076A1 (en) 2012-09-27
MX2007013584A (es) 2008-04-22
JP2008539271A (ja) 2008-11-13
CA2605745A1 (en) 2006-11-02
US20080206140A1 (en) 2008-08-28
US9006396B2 (en) 2015-04-14
AU2006239318A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
BRPI0607676A2 (pt) anticorpos contra isoformas de cspcna e usos destes
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
EA200970210A1 (ru) Prlr-специфическое антитело и его применения
BR112012019693A2 (pt) anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
AR057237A1 (es) Metodos y composiciones para actuar sobre la poliubiquitina
AR057253A1 (es) Anticuerpos anti-ox40l y metodos que los utilizan
CR20150088A (es) Anticuerpos anti-notch1 nrr
BR112012031071A2 (pt) 8-proteínas de ligação à il-1
SV2008002972A (es) Composiciones, metodos y usos de anticuerpos humanos anti-il-23 ref. cen5117sv
ECSP099619A (es) Anticuerpos anti-robo4 y sus usos
BRPI0607323B8 (pt) composições, usos de polipeptídeos e de anticorpos, bem como kits para a detecção de anticorpo que se liga especificamente a um polipeptídeo
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
UY31533A1 (es) Moleculas de enlace al receptor humano ox40
BRPI0810096A2 (pt) Anticorpo anti-epcam e seus usos
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
DE602006020544D1 (de) Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs
BRPI0812488A2 (pt) Anticorpos anti-cd44 humanizados e quiméricos que mediam citotoxidade de célula de câncer, usos dos mesmos, ensaios de ligação, métodos, composições e kit de ensaio
ECSP088743A (es) Anticuerpos para egfl7 y métodos para su uso
BR112019010128A2 (pt) proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas
CR9853A (es) Compuestos de exemestano (s)-6-metiloxaalquilo y metodos relacionados con su utilizacion
BR112012033163A2 (pt) ''anticorpos monoclonais, linhagens celulares, usos de um anticorpo, kit, métodos para detectar um anticorpo, composição de anticorpo e uso de uma composição de anticorpo''
BRPI0510561A (pt) epìtopos que induzem morte de célula t
AR059447A1 (es) Metodos y composiciones para actuar sobre relt (receptor expresado en tejidos linfoides)
EA200800144A1 (ru) МОДИФИКАЦИИ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B12C Appeal against dismissal [chapter 12.3 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]